China's CStone Pharma set for best day in over 7 weeks on new drug application

23
3
Favorite

China's CStone Pharma set for best day in over 7 weeks on new drug application

Reuters2021-09-02

** Shares of immuno-oncology drugs developer CStone Pharmaceuticals jump 9.3% to HK$13.90, the biggest daily percentage gain since July 12

** Stock on track to snap two consecutive sessions of decline

** Shanghai-based company says National Medical Products Administration of China has accepted its new drug application (NDA) for sugemalimab as a consolidation therapy in patients with unresectable stage III cell lung cancer, its eighth NDA/supplemental NDA submitted by CStone ()

** Says CStone has formed a strategic partnership with Pfizer that includes development and commercialization of sugemalimab in mainland China and a framework to bring additional oncology assets to the Greater China market

** Hong Kong's healthcare index falls 1.2%

** The Hang Seng China Enterprises Index gains 0.7% and the benchmark index is up 0.1%

** As of last close, the stock had surged 26.2% this year

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Report

Comment（3）

Jensenkhew9449
·2021-09-02
Like
Reply
1
Report
THB
·2021-09-02
[Cry]
Reply
2
Report
Fold Replies
- THB:
  h
  2021-09-02
  Reply
  Report
Leex5
·2021-09-02
Pls like
Reply
2
Report
Fold Replies
- mrspid3r:
  Like pls
  2021-09-02
  Reply
  Report

Most Discussed

7x24

All

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"data":{"share":"https://ttm.financial/m/news/2164843414?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2021-09-02 15:07","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2164843414","market":"hk","top_or_hot":-1,"title":"China's CStone Pharma set for best day in over 7 weeks on new drug application","media":"Reuters","content":"<p>** Shares of immuno-oncology drugs developer CStone Pharmaceuticals jump 9.3% to HK$13.90, the biggest daily percentage gain since July 12</p>\n<p>** Stock on track to snap two consecutive sessions of decline</p>\n<p>** Shanghai-based company says National Medical Products Administration of China has accepted its new drug application (NDA) for sugemalimab as a consolidation therapy in patients with unresectable stage III cell lung cancer, its eighth NDA/supplemental NDA submitted by CStone ()</p>\n<p>** Says CStone has formed a strategic partnership with Pfizer that includes development and commercialization of sugemalimab in mainland China and a framework to bring additional oncology assets to the Greater China market</p>\n<p>** Hong Kong's healthcare index falls 1.2%</p>\n<p>** The Hang Seng China Enterprises Index gains 0.7% and the benchmark index is up 0.1%</p>\n<p>** As of last close, the stock had surged 26.2% this year</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>China's CStone Pharma set for best day in over 7 weeks on new drug application</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nChina's CStone Pharma set for best day in over 7 weeks on new drug application\n</h2>\n\n<h4 class=\"meta\">\n\n2021-09-02 15:07 北京时间&nbsp;&nbsp;&nbsp;<strong>Reuters</strong>\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>** Shares of immuno-oncology drugs developer CStone Pharmaceuticals jump 9.3% to HK$13.90, the biggest daily percentage gain since July 12\n** Stock on track to snap two consecutive sessions of decline...</p>\n\n<a href=\"None\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02616","symbol_name":"基石药业-B","start_time":0,"source_url":null,"article_id":"2164843414","we_media_id":"1036604489","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2164843414","pubTimestamp":1630566466,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"summary":"** Shares of immuno-oncology drugs developer CStone Pharmaceuticals jump 9.3% to HK$13.90, the bigge","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02616":"基石药业-B","PFE":"辉瑞"},"translate_title":"中国CStone制药创7周以来新药申请最佳日","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02616":0.9,"PFE":0.9},"content_text":"** Shares of immuno-oncology drugs developer CStone Pharmaceuticals jump 9.3% to HK$13.90, the biggest daily percentage gain since July 12\n** Stock on track to snap two consecutive sessions of decline\n** Shanghai-based company says National Medical Products Administration of China has accepted its new drug application (NDA) for sugemalimab as a consolidation therapy in patients with unresectable stage III cell lung cancer, its eighth NDA/supplemental NDA submitted by CStone ()\n** Says CStone has formed a strategic partnership with Pfizer that includes development and commercialization of sugemalimab in mainland China and a framework to bring additional oncology assets to the Greater China market\n** Hong Kong's healthcare index falls 1.2%\n** The Hang Seng China Enterprises Index gains 0.7% and the benchmark index is up 0.1%\n** As of last close, the stock had surged 26.2% this year","kind":"highlight","is_publish_news":true,"is_publish_highlight":true,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":812817669,"gmtCreate":1630572894751,"gmtModify":1676530344113,"author":{"id":"3581212122538655","authorId":"3581212122538655","name":"Jensenkhew9449","avatar":"https://static.tigerbbs.com/e3b82a9dec9b02a89965fe700e283bb7","vip":1,"crmLevel":2,"crmLevelSwitch":0,"authorIdStr":"3581212122538655","idStr":"3581212122538655"},"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/812817669","repostId":2164843414,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":812800662,"gmtCreate":1630569804756,"gmtModify":1676530342900,"author":{"id":"3582189889665842","authorId":"3582189889665842","name":"THB","avatar":"https://static.tigerbbs.com/714f3e61faee0b8a2ef01897bed9705d","vip":1,"crmLevel":2,"crmLevelSwitch":0,"authorIdStr":"3582189889665842","idStr":"3582189889665842"},"htmlText":"[Cry]&nbsp;","listText":"[Cry]&nbsp;","text":"[Cry]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/812800662","repostId":2164843414,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5728448,"gmtCreate":1630569813985,"gmtModify":1663233275227,"authorId":3582189889665842,"author":{"id":3582189889665842,"idStr":"3582189889665842","authorId":3582189889665842,"name":"THB","avatar":"https://static.tigerbbs.com/714f3e61faee0b8a2ef01897bed9705d","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":812800662,"type":1,"supId":0,"prevId":0,"content":"h","text":"h","html":"h"}],"langContent":"EN"},{"id":812179096,"gmtCreate":1630568989115,"gmtModify":1676530342682,"author":{"id":"4087555676656730","authorId":"4087555676656730","name":"Leex5","avatar":"https://static.tigerbbs.com/78ab91ec8474952a2dd7928822293608","vip":1,"crmLevel":2,"crmLevelSwitch":0,"authorIdStr":"4087555676656730","idStr":"4087555676656730"},"htmlText":"Pls like","listText":"Pls like","text":"Pls like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/812179096","repostId":2164843414,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5728495,"gmtCreate":1630570206437,"gmtModify":1663233278433,"authorId":3565908625782607,"author":{"id":3565908625782607,"idStr":"3565908625782607","authorId":3565908625782607,"name":"mrspid3r","avatar":"https://static.tigerbbs.com/f793da3874744ba810961fb9ca31eed4","vip":1,"currentWearingBadge":{"badgeId":"972123088c9646f7b6091ae0662215be-2","templateUuid":"972123088c9646f7b6091ae0662215be","name":"Master Trader","description":"Total number of securities or futures transactions reached 100","bigImgUrl":"https://static.tigerbbs.com/ad22cfbe2d05aa393b18e9226e4b0307","smallImgUrl":"https://static.tigerbbs.com/36702e6ff3ffe46acafee66cc85273ca","grayImgUrl":"https://static.tigerbbs.com/d52eb88fa385cf5abe2616ed63781765","redirectLinkEnabled":0,"hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":"80.13%","individualDisplayEnabled":0,"individualDisplaySort":0,"categoryType":1100},"crmLevel":2,"crmLevelSwitch":1,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":812179096,"type":1,"supId":0,"prevId":0,"content":"Like pls","text":"Like pls","html":"Like pls"}],"langContent":"EN"}],"hasMoreComments":true,"newsSizeData":{"likeSize":23,"commentSize":3,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false}}